Rein Therapeutics Inc. (NASDAQ:RNTX) Given Average Recommendation of “Hold” by Analysts

Posted by on Jul 20th, 2026

Shares of Rein Therapeutics Inc. (NASDAQ:RNTX – Get Free Report) have been given a consensus rating of “Hold” by the four research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $6.00.

A number of brokerages have recently weighed in on RNTX. Wall Street Zen upgraded Rein Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. HC Wainwright reduced their price objective on shares of Rein Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Maxim Group assumed coverage on shares of Rein Therapeutics in a report on Monday. They issued a “buy” rating and a $4.00 price objective for the company. Finally, Weiss Ratings cut shares of Rein Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday.

Check Out Our Latest Research Report on RNTX

Institutional Trading of Rein Therapeutics

Several large investors have recently bought and sold shares of the company. Chicago Partners Investment Group LLC grew its stake in shares of Rein Therapeutics by 32.2% in the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock worth $53,000 after buying an additional 10,000 shares in the last quarter. Gagnon Securities LLC lifted its holdings in shares of Rein Therapeutics by 5.0% in the 4th quarter. Gagnon Securities LLC now owns 240,220 shares of the company’s stock valued at $279,000 after acquiring an additional 11,528 shares during the last quarter. Susquehanna International Group LLP bought a new position in shares of Rein Therapeutics in the 3rd quarter valued at about $35,000. HRT Financial LP purchased a new position in Rein Therapeutics in the fourth quarter worth about $38,000. Finally, Geode Capital Management LLC grew its position in Rein Therapeutics by 15.1% in the fourth quarter. Geode Capital Management LLC now owns 284,555 shares of the company’s stock worth $330,000 after acquiring an additional 37,244 shares in the last quarter. 90.89% of the stock is owned by institutional investors.

Rein Therapeutics Stock Performance

NASDAQ:RNTX traded down $0.01 during midday trading on Monday, reaching $0.85. 554,610 shares of the stock traded hands, compared to its average volume of 433,444. The stock has a market capitalization of $72.54 million, a P/E ratio of -0.45 and a beta of 1.35. The company has a fifty day moving average of $0.99 and a 200 day moving average of $1.20. Rein Therapeutics has a 12 month low of $0.83 and a 12 month high of $2.18.

Rein Therapeutics (NASDAQ:RNTX – Get Free Report) last posted its earnings results on Friday, May 15th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.30. On average, analysts predict that Rein Therapeutics will post -0.53 EPS for the current fiscal year.

About Rein Therapeutics

(Get Free Report)

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.

Read More

Receive News & Ratings for Rein Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rein Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.